# Psychological Distress in COPD Assessed by DASS-21-R: Multivariable Regression and Bayesian Analysis Across GOLD Stages

**Authors:** Adina Deliu, Luana Alexandrescu, Bogdan Cimpineanu, Oana Cristina Arghir, Sanda Jurja, Ioan Tiberiu Tofolean, Rodica Gabriela Enache, Ioana Gherghisan, Ionela Preotesoiu, Ionut Valentin Stanciu, Andreea Nelson Twakor, Monica Cordos, Alexandra Herlo, Daria Maria Alexandrescu, Doina Ecaterina Tofolean

PMC · DOI: 10.3390/medsci14010147 · Medical Sciences · 2026-03-19

## TL;DR

The study finds that psychological distress in COPD patients is not linked to disease severity but is more connected to symptom burden.

## Contribution

This study introduces a novel approach combining multinomial regression and Bayesian analysis to assess psychological distress in COPD across GOLD stages.

## Key findings

- COPD severity was not independently associated with depression, anxiety, or stress.
- Symptom burden, measured by CAT scores, was strongly linked to psychological distress.
- Bayesian analyses showed minimal differences in psychological distress scores between COPD severity groups.

## Abstract

Background: Psychological distress is a common comorbidity in chronic obstructive pulmonary disease (COPD), yet its relationship with disease severity remains incompletely understood. This study aimed to assess depression, anxiety, and stress using the Depression Anxiety Stress Scales–21 (DASS-21) and to examine their distribution across COPD severity stages. Methods: This multicenter, cross-sectional observational study included 285 clinically stable COPD patients enrolled between 2023 and 2025. COPD severity was classified according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. Multinomial and binary logistic regression models were constructed to identify independent predictors of COPD severity and clinically significant psychological distress, adjusting for demographic and clinical covariates. Bayesian independent sample analyses and ANOVA effect size estimates were additionally performed. Results: Smoking exposure was independently associated with advanced COPD stages (GOLD 4 vs. GOLD 1–3: aOR 1.05, p < 0.001), as was dyspnea severity (mMRC: aOR 14.66, p < 0.001). In multivariable models examining psychological outcomes, COPD severity was not independently associated with clinically significant depression (p = 0.899), anxiety (p = 0.460), or stress (p = 0.843). In contrast, symptom burden measured using the COPD Assessment Test (CAT) score was consistently associated with depression (aOR 1.133, p < 0.001), anxiety (aOR 1.179, p < 0.001), and stress (aOR 1.144, p < 0.001). ANOVA effect sizes across GOLD stages were small (η2 ≤ 0.047), and Bayesian analyses provided moderate to strong evidence supporting minimal differences in DASS-21-R scores between severity groups. Conclusions: Psychological distress is prevalent across all COPD severity stages and is not independently determined by airflow limitation. Symptom burden rather than spirometric severity appears to be more closely associated with emotional outcomes.

## Linked entities

- **Diseases:** chronic obstructive pulmonary disease (MONDO:0005002), COPD (MONDO:0005002)

## Full-text entities

- **Genes:** CAT (catalase) [NCBI Gene 847], IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** airway injury (MESH:D000402), cardiac failure (MESH:D006333), asthma (MESH:D001249), elevated blood pressure (MESH:D006973), respiratory disease (MESH:D012140), pulmonary tuberculosis (MESH:D014397), Anxiety (MESH:D001007), respiratory dysfunction (MESH:D012131), pulmonary fibrosis (MESH:D011658), structural lung impairment (MESH:D020914), inflammation (MESH:D007249), GOLD 4 disease (OMIM:609400), pulmonary embolism (MESH:D011655), GOLD 4 (MESH:D053632), Symptom (MESH:D012816), functional (MESH:D003291), Atrial fibrillation or flutter (MESH:D001282), Psychological (MESH:D000067073), and cognitive dysfunction (MESH:D003072), mood disturbances (MESH:D019964), anxiety symptoms (MESH:D001008), psychiatric (MESH:D001523), Diabetes (MESH:D003920), pulmonary dysfunction (MESH:D011660), COPD (MESH:D029424), Psychological Distress (MESH:D012128), Dyspnea (MESH:D004417), bronchiectasis (MESH:D001987), pulmonary diseases (MESH:D008171), Emotional disturbances (MESH:D014832), neurodegenerative (MESH:D019636), stress (MESH:D000079225), interstitial lung disease (MESH:D017563), Hypoventilation (MESH:D007040), injury to (MESH:D014947), acute lower respiratory infection (MESH:D012141), heart disease (MESH:D006331), pulmonary inflammation (MESH:D011014), obesity (MESH:D009765), Depression (MESH:D003866)
- **Chemicals:** CO2 (MESH:D002245), BioRender (-), O2 (MESH:D010100)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13028331/full.md

## Figures

14 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13028331/full.md

## References

48 references — full list in the complete paper: https://tomesphere.com/paper/PMC13028331/full.md

---
Source: https://tomesphere.com/paper/PMC13028331